Approximately 50% of HER2-positive breast cancers are ER-positive, exhibiting distinct treatment responses and prognoses from ER-negative cases [4–7], partly influenced by bidirectional crosstalk between the HER2 and ER pathways [8]. This evidence concerns the gene ERBB2 and breast cancer.